utilized ovarian cancer patient‐derived organoid models to create nanoparticles, Abplatin (iv), by combining Pt (IV) prodrug with human serum albumin (HSA).[299] This nanodrug not only achieved low toxicity and targeted delivery but also showed significant antitumor effects against platinum‐resistant tumor cells in ovarian cancer organoids. This evidence concerns the gene ALB and ovarian carcinoma.